Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
10.50
-0.01 (-0.10%)
At close: Oct 27, 2025, 4:00 PM EDT
10.30
-0.20 (-1.90%)
After-hours: Oct 27, 2025, 4:13 PM EDT
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $18.31M in the quarter ending June 30, 2025, with 1.91% growth. This brings the company's revenue in the last twelve months to $64.81M, down -9.94% year-over-year. In the fiscal year ending September 30, 2024, Enanta Pharmaceuticals had annual revenue of $67.64M, down -14.61%.
Revenue (ttm)
$64.81M
Revenue Growth
-9.94%
P/S Ratio
3.45
Revenue / Employee
$494,702
Employees
131
Market Cap
292.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ENTA News
- 7 days ago - Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire
- 20 days ago - Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire
- 25 days ago - Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 26 days ago - Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 26 days ago - Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Business Wire
- 27 days ago - Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals, Inc. - Special Call - Seeking Alpha
- 4 weeks ago - Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change - Seeking Alpha